`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`v.
`BAUSCH HEALTH IRELAND LIMITED,
`
`Patent Owner.
`____________________
`
`Case No. IPR2022-01102
`U.S. Patent No. 9,610,321
`____________________
`
`PATENT OWNER’S MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`Case No. IPR2022-01102
`U .S. Patent No. 9,610,321
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Bausch Health Ireland
`
`Limited ("Bausch Health") hereby submits the following mandatory notices in
`
`connection with this proceeding.
`
`I.
`
`BAUSCH HEALTH'S POWER OF ATTORNEY
`
`A Power of Attorney appointing lead and back-up counsel is being filed
`
`concurrently with these notices.
`
`II. BAUSCH HEALTH'S MANDATORY NOTICES
`
`(a)
`
`37 C.F.R. § 42.S(b)(l): Real Parties-in-Interest
`
`The real parties-in-interest for the Patent Owner are Bausch Health Ireland
`
`Limited and Salix Pharmaceuticals, Inc.
`
`(b)
`
`37 C.F.R. § 42.8(b)(2): Related Matters
`
`1. Judicial
`
`The patent challenged here, U.S. Patent 9,610,321 ("the '321 patent"), has
`
`been asserted in the following litigations:
`
`Case Caption
`Bausch Health Ireland Limited and
`Salix Pharmaceuticals, Inc. v. MSN
`Laboratories Private and MSN
`Pharmaceuticals Inc.
`
`Case No.
`
`Court
`
`Filed
`
`2:21-cv-10057
`
`D.N.J.
`
`April 22, 2021
`
`2
`
`
`
`Case No. IPR2022-01 102
`U.S. Patent No. 9,610,321
`
`Case No.
`
`Court
`
`Filed
`
`2:21-cv-10403
`
`D.N.J.
`
`April 28, 2021
`(Transferred
`toN.D.
`W.Va.)
`
`1:21-cv-00611
`
`D. Del.
`
`April 29, 2021
`
`2:21-cv-00573
`
`W.D.Pa. April 30, 2021
`
`1 :22-cv-00020
`
`N.D.W.Va.
`
`March 9, 2022
`(Transferred
`from D.N .J.)
`
`Case Caption
`Bausch Health Ireland Limited and
`Salix Pharmaceuticals, Inc. v.
`Mylan Laboratories Ltd., Agila
`Specialties Inc., Mylan API US
`LLC, Mylan Inc., Viatris Inc., and
`Mylan Pharmaceuticals Inc. - A
`Viatris Company (transferred to
`N D.WV.)
`Bausch Health Ireland Limited and
`Salix Pharmaceuticals, Inc. v.
`Mylan Laboratories Ltd., Agila
`Specialties Inc., Mylan API US
`LLC, Mylan Inc., Viatris Inc., and
`Mylan Pharmaceuticals Inc. - A
`Viatris Company
`Bausch Health Ireland Limited and
`Salix Pharmaceuticals, Inc. v.
`Mylan Laboratories Ltd., Agila
`Specialties Inc., Mylan API US
`LLC, Mylan Inc., Viatris Inc., and
`Mylan Pharmaceuticals Inc. - A
`Viatris Company
`Bausch Health Ireland Limited and
`Salix Pharmaceuticals, Inc. v.
`Mylan Laboratories Ltd., Agila
`Specialties Inc., Mylan API US
`LLC, Mylan Inc., Viatris Inc., and
`Mylan Pharmaceuticals Inc. - A
`Viatris Company
`
`2. Administrative
`
`Petitioner filed additional petitions for inter partes review involving patents
`
`closely related to the challenged patent.
`
`3
`
`
`
`Case No. IPR2022-01102
`U .S. Patent No. 9,6 10,321
`
`Case Caption
`
`IPR No.
`
`Patent
`
`Filed
`
`Mylan Pharmaceuticals Inc. v.
`Bausch Health Ireland Limited
`
`Mylan Pharmaceuticals Inc. v.
`Bausch Health Ireland Limited
`Mylan Pharmaceuticals Inc. v.
`Bausch Health Ireland Limited
`Mylan Pharmaceuticals Inc. v.
`Bausch Health Ireland Limited
`
`IPR2022-00722
`
`7,041 ,786
`
`IPR2022-01103
`
`IPR2022-01104
`
`IPR2022-01105
`
`9,616,097
`
`9,919,024
`
`9,925,23 1
`
`March 2 1,
`2022
`
`June 10,
`2022
`June 10,
`2022
`June 10,
`2022
`
`37 C.F.R. § 42.8(b)(3) and (4): Lead and Back-Up Counsel, and
`(c)
`Service Information
`
`Bausch Health designates the following counsel to transact all business in the
`
`United States Patent & Trademark Office associated with the above-captioned
`
`proceeding.
`
`Lead Counsel
`Justin J. Hasford (Reg. No. 62,180)
`justin.hasford@finnegan.com
`FINNEGAN, HENDERSON, F ARABOW,
`G ARRETT & DUNNER, L.L.P.
`901 New York Avenue, NW
`Washington, DC 20001-441 3
`(202) 408-41 75
`Tel:
`(202) 408-4400
`Fax:
`
`Back-Up Counsel
`Bryan C. Diner (Reg. No. 32,409)
`bryan.diner@finnegan .com
`FINNEGAN, HENDERSON, F ARABOW,
`G ARRETT & DUNNER, L.L.P.
`901 New York Avenue, NW
`Washington, DC 20001 -441 3
`(202) 408-4116
`Tel:
`(202) 408-4400
`Fax:
`
`Please address all correspondence regarding this proceeding to lead and back(cid:173)
`
`up counsel at the addresses listed above. Bausch Health also consents to electronic
`
`service by email.
`
`4
`
`
`
`
`
`Dated: June 30, 2022
`
`
`
`
`
`Case No. IPR2022-01102
`U.S. Patent No. 9,610,321
`
`
`
`Respectfully submitted,
`
`
`By: /Justin J. Hasford/
`Justin J. Hasford, Reg. No. 62,180
`Lead Counsel
`Bryan C. Diner, Reg. No. 32,409
`Back-up Counsel
`
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, L.L.P.
`901 New York Ave. NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner
`
`5
`
`
`
`
`
`Case No. IPR2022-01102
`U.S. Patent No. 9,610,321
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Mandatory Notices Pursuant to 37 C.F.R. § 42.8 was served on June 30, 2022,
`
`via email directed to counsel of record for the Petitioner at the following:
`
`Jad A. Mills
`Wilson Sonsini Goodrich & Rosati PC
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`jmills@wsgr.com
`4863-5899-2145@mail.vault.netdocuments.com
`
`Richard Torczon
`Wilson Sonsini Goodrich & Rosati PC
`1700 K Street N.W., 5th Floor
`Washington, DC 20006
`rtorczon@wsgr.com
`
`Nicole W. Stafford
`Dennis D. Gregory
`Wilson Sonsini Goodrich & Rosati PC
`900 South Capital of Texas Highway, Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`nstafford@wsgr.com
`dgregory@wsgr.com
`
`Petitioner consents to electronic-mail service.
`
`
`
`
`Date: June 30, 2022
`
`
`
`
`
`
`
`
`
`/Geneva Eaddy/
`Geneva Eaddy
`Case Manager
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER LLP
`
`